Revvity, Inc. (RVTY) Stock Price & How to Invest

Last updated November 2026

Short answer

Revvity (NYSE: RVTY) is a Waltham, Massachusetts health-sciences company that sells research reagents, detection and high-content imaging instruments, scientific software, and the immunoassay and newborn-screening products that run in hospital and public-health laboratories. The registrant was called PerkinElmer until 2023 and EDGAR still files it under SIC 3826, Laboratory Analytical Instruments, which is the single thing a screener gets wrong here: the analytical-instruments, food-testing and enterprise-services businesses went to New Mountain Capital in March 2023 for ~$2.136 billion at closing, and the buyer took the PerkinElmer name with them. What is left splits almost exactly down the middle, ~$720.5 million of Life Sciences revenue and ~$720.3 million of Diagnostics revenue in the first half of fiscal 2026. As of November 20, 2026 the shares closed near $145.23, up about 48% year to date, for a market value of about $16.2 billion.

RVTY stock price

As of 2026-11-20, Revvity, Inc. (RVTY) last closed at $145.22, up 47.8% over the past year. Over the past 52 weeks it has traded between $82.26 and $165.78.

RVTY last close
$145.22
1 day
-4.20%
1 month
-7.27%
1 year
+47.78%
52-week range
$82.26 to $165.78
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Revvity, Inc.'s investor relations page. Walnut is informational, not investment advice.

RVTY key stats

At $145.22 on November 20, 2026, Revvity, Inc. (RVTY) has a market cap of $16.2B, a P/E of 64.5 on trailing earnings (24.4 on forward earnings) and a dividend yield of 0.19%. It next reports earnings around February 1, 2027 (estimated).

Market cap
$16.2B
P/E (trailing)
64.5
P/E (forward)
24.4
EPS (trailing 12 months)
$2.25
Price to book
2.2
Dividend yield
0.19%
Beta
1.09
Next earnings
around February 1, 2027 (estimated)

Market cap, P/E and yield are measured at the $145.22 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Revvity, Inc. (RVTY)?

The last two weeks for Revvity, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • RVTY closed at $145.22 on November 20, 2026, down 5.9% over the past five trading days (from $154.39).
  • Revvity, Inc. next reports quarterly results around February 1, 2027 (estimated).
  • On November 13, 2026, Revvity, Inc. filed an 8-K with the SEC reporting information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
  • On November 10, 2026, Revvity, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 16, 2026, JP Morgan raised its target to $165.00 from $160.00 (Neutral).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Revvity, Inc. (RVTY) do?

Revvity runs two reporting segments of nearly identical size. Life Sciences sold ~$720.5 million in the first half of fiscal 2026 and covers two product lines: Life Sciences Solutions (~$601.0 million), meaning reagents, assays, labeling and detection chemistry, automation and high-content imaging systems such as the Opera Phenix platform, and Signals software (~$119.5 million), a scientific informatics suite sold on subscription to pharmaceutical R&D organizations. Diagnostics sold ~$720.3 million over the same period and also splits two ways: immunodiagnostics (~$416.6 million), largely the EUROIMMUN autoimmune, allergy and infectious-disease immunoassay franchise, and reproductive health (~$303.7 million), which is newborn screening, prenatal testing and related genomic services. Customers are pharmaceutical and biotech R&D groups, clinical and public-health laboratories, academia and governments across more than 160 countries, served by roughly 11,000 employees. Geography is spread wide rather than concentrated: in the June quarter the Americas produced ~$325.6 million, Europe ~$229.0 million and Asia ~$175.1 million. A large share of revenue is consumable or subscription in nature, since assays, reagents and screening kits get bought again every period, while instruments and software licenses carry the cyclical part of the business.

The investment picture turns on three things: whether Diagnostics keeps compounding, whether pharma instrument and software spending recovers, and how much of the GAAP earnings gap an owner is willing to look through. Revenue has been close to flat over three fiscal years, ~$2.751 billion in 2023, ~$2.755 billion in 2024 and ~$2.856 billion in 2025, so the equity story has been margin, buybacks and mix rather than volume. Adjusted operating margin ran 28.9% in the June quarter against a GAAP operating margin of 12.2%, and the wedge between them is ~$84.9 million of quarterly intangible amortization sitting on ~$6.61 billion of goodwill and ~$2.22 billion of net intangibles, the accounting residue of the acquisition spree that built EUROIMMUN, BioLegend and the Signals portfolio. Management raised full-year guidance on August 4, 2026 to 4% to 5% pro forma organic growth and $5.30 to $5.40 of pro forma adjusted EPS. Guidance is now stated excluding the China immunodiagnostics business, which is under a signed agreement to be sold, so the guided revenue base and the reported revenue base are no longer the same thing.

The third quarter kept the pattern of small beats. For the quarter ended October 4, 2026, revenue was ~$709.6 million, up about 4.3% year over year and above the ~$695 million consensus, adjusted EPS was $1.37 against an estimate of $1.30, and GAAP net income was ~$62.3 million. That makes four straight quarters of adjusted EPS ahead of estimates. The share price has cooled since the October peak: RVTY closed at about $145.23 on November 20, 2026, down about 8.5% over the past month but up about 16% over three months and about 48% year to date, after touching a 52-week high of about $171.74. Analysts kept lifting targets after the report, with Barclays moving to $175 from $160 on November 4, and the mean target of about $171.40 across 15 analysts now sits above the share price with a consensus buy rating. Revvity held a 2026 Investor Day on November 13 under the theme "Powering Scientific Intelligence" to present its long-range outlook. The next report, for the fourth quarter, is expected around February 1, 2027, with consensus at about $1.62 of adjusted EPS on about $762 million of revenue.

What's driving Revvity, Inc. (RVTY)?

1. Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics

Diagnostics revenue reached ~$371.0 million in the quarter ended July 5, 2026, up from ~$354.4 million a year earlier, and grew 12% on a pro forma basis with 11% pro forma organic growth. Reproductive health was the strongest line at ~$156.2 million against ~$135.6 million, a gain of ~15%, helped by newborn screening volumes and a Genomics England sequencing contract that management sized at roughly $25 million for full-year 2026 on the August earnings call. Segment adjusted operating income rose to ~$112.9 million from ~$89.4 million, taking margin from 25.2% to 30.4%, an improvement of 520 basis points that the 10-Q attributes to tariff refunds and cost containment. For the half, Diagnostics adjusted operating income was ~$189.0 million on ~$720.3 million of revenue.

2. The China immunodiagnostics exit resets the base

On July 31, 2026 Revvity signed a definitive agreement to divest its immunodiagnostics business in China, disclosed in the 10-Q as roughly 6% of fiscal 2025 revenue, with closing expected by the end of 2027 subject to regulatory approval. Chief executive Prahlad Singh described China as a structurally more difficult environment for that unit. The immediate effect is presentational and material: forward guidance is given only on a pro forma basis that strips the unit out, so full-year 2026 pro forma revenue of $2.83 to $2.86 billion sits below the ~$2.91 billion the company actually collected over the twelve months to July 5, 2026 (~$2.94 billion through October 4). Immunodiagnostics outside China grew high single digits in the quarter even with tuberculosis testing pressure in the Americas. Asia revenue fell to ~$175.1 million from ~$193.1 million year over year.

3. Software is the swing factor inside Life Sciences

Signals software revenue was ~$57.7 million in the June quarter against ~$67.8 million a year earlier, a decline of roughly 15% as reported and about 20% organically, which management attributed to a hard comparison and contract timing rather than lost accounts. Annual platform value continues to grow at a double-digit rate by the company's account, and management guided to a return to double-digit software growth in the second half. Revvity bought Advanced Chemistry Development (ACD/Labs) of Toronto in the first quarter of 2026 for $72.0 million in cash plus up to $8.0 million of contingent consideration, adding analytical characterization and molecular design software to the segment. A Signals AI release with an Anthropic Claude connector went out during the quarter. Life Sciences overall fell 3% organically, with reagents roughly flat at ~$301.0 million.

4. Share count is shrinking and the balance sheet is getting lighter

Revvity spent ~$820.8 million on buybacks in fiscal 2025 and another ~$102.5 million in the first half of 2026. Weighted average diluted shares fell to ~111.7 million for the six months ended July 5, 2026 from ~118.9 million a year earlier, a reduction of about 6%, which is why adjusted EPS grows faster than adjusted operating income. In July 2026 the company repaid its EUR 500.0 million 1.875% senior notes at maturity for ~$571.2 million in cash, which retired the only near-term maturity and left ~$2.65 billion of principal running out to 2028 through 2051. Management put net leverage at approaching 2x on the call. Operating cash flow from continuing operations was ~$317.8 million in the half against ~$268.4 million, with capital expenditure of only ~$30.8 million.

What are the risks to Revvity, Inc. (RVTY)?

The most immediate risk is that a chunk of 2026 profit does not repeat. Following the Supreme Court's February 20, 2026 ruling that the International Emergency Economic Powers Act does not authorize tariffs, Revvity applied through the Customs and Border Protection refund process for $20.2 million and had received $16.2 million by July 5, 2026. The company books these on receipt and has recorded no refund receivable, and the full $16.2 million landed in cost of revenue in a single quarter, worth roughly $0.11 of the $1.41 adjusted EPS and a good part of the 260 basis points of gross margin expansion. Second, the end market has not fully turned. Pharma and biotech sales declined mid-single digits including software in the quarter, academic and government budgets remain unsettled, and instruments are a deferrable purchase when customers are cautious. Third, the China divestiture is signed but not closed, with completion expected only by the end of 2027 and conditioned on regulatory approval, so Revvity carries the unit's declining results in the meantime while guiding without it. Fourth, the balance sheet is intangible-heavy: ~$6.61 billion of goodwill and ~$2.22 billion of net intangibles against ~$12.05 billion of total assets and ~$7.23 billion of equity, which leaves real impairment exposure if any acquired franchise underperforms. Fifth, restructuring is ongoing and disruptive, with severance actions in the first half of 2026 touching roughly 5% of the workforce and ~$46.2 million of charges recorded. Sixth, reproductive health revenue is tied to birth rates and to public-health screening budgets, both outside the company's control, and tuberculosis testing in the Americas is already a stated drag. Debt is ~$2.65 billion after the July repayment, with interest expense of ~$47.7 million in the half. Finally, after a roughly 48% gain in 2026 the stock trades near $145 and at about 24 times expected 2027 earnings, a premium to its own history that leaves little room for a guidance miss, and the shares already fell about 8.5% in the month to November 20 despite a third-quarter beat. Reported revenue growth was only about 4.3% in that quarter, so most of the earnings growth still has to come from margin and share count.

What is the Revvity, Inc. (RVTY) forecast?

15 analysts publish price targets on RVTY, averaging $171.40 as of November 2026, or +18.0% against the $145.22 share price on November 20, 2026. The published targets run from $122.00 to $200.00, a moderate spread, and the ratings split 6 buy, 11 hold, 1 sell. Over the last six months there have been 10 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RVTY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is RVTY a buy or a sell?

We give no verdict on Revvity, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics. Diagnostics revenue reached ~$371.0 million in the quarter ended July 5, 2026, up from ~$354.4 million a year earlier, and grew 12% on a pro forma basis with 11% pro forma organic growth. The most optimistic published target, $200.00, assumes this works close to its best case.

The case against. The most immediate risk is that a chunk of 2026 profit does not repeat. The most pessimistic target, $122.00, is roughly what RVTY is worth if this bites instead.

Read the full bull and bear case on RVTY, including what would have to change to break either one. Walnut is not an investment adviser.

Has Revvity, Inc. (RVTY) split its stock?

No. Revvity, Inc. (RVTY) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Revvity, Inc. (RVTY) valued?

Market cap, P/E and dividend yield at today's price are in the RVTY key stats above. The business figures below come from Revvity, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$2.94 billion for the twelve months to October 4, 2026, with third-quarter revenue of ~$709.6 million up about 4.3% year over year and above the ~$695 million consensus. Growth has been slow rather than absent: ~$2.751 billion in fiscal 2023, ~$2.755 billion in fiscal 2024 and ~$2.856 billion in fiscal 2025. Analysts expect ~$2.87 billion for fiscal 2026 and ~$3.04 billion for 2027. Note that fiscal 2026 ends January 3, 2027 and contains 53 weeks, one more than fiscal 2025.
  • GAAP earnings versus adjusted earnings: Trailing twelve-month net income is ~$253 million and trailing diluted EPS ~$2.25, against $2.07 for full-year 2025 and $2.20 for 2024. Adjusted EPS was $1.37 in the September quarter against a $1.30 estimate, after $1.41 against $1.22 in the June quarter and $1.06 against $1.01 in the March quarter. In the June quarter the bridge was $0.76 of intangible amortization, $0.32 of restructuring, $0.05 of investment mark-to-market and $0.02 of purchase accounting, less $0.21 of tax. Consensus adjusted EPS is ~$5.44 for 2026 and ~$5.96 for 2027; in August management had guided 2026 pro forma adjusted EPS to $5.30 to $5.40.
  • Margins: On Yahoo Finance's trailing basis, gross margin is ~55.9%, GAAP operating margin ~16.7% and net margin ~8.6%. Adjusted operating margin ran 28.9% in the June quarter against a GAAP operating margin of 12.2%, the gap being intangible amortization from past acquisitions.
  • Segment and product-line mix: First-half 2026 revenue splits almost evenly, Life Sciences ~$720.5 million and Diagnostics ~$720.3 million. Within Life Sciences: Life Sciences Solutions ~$601.0 million and Signals software ~$119.5 million. Within Diagnostics: immunodiagnostics ~$416.6 million and reproductive health ~$303.7 million. Segment adjusted operating margins in the June quarter were 31.1% for Life Sciences (down from 31.6%) and 30.4% for Diagnostics (up from 25.2%).
  • Cash flow and balance sheet: Trailing operating cash flow is ~$656 million and free cash flow ~$633 million on Yahoo Finance's basis, against ~$589.0 million of operating cash flow for full-year 2025. Cash stood at ~$593 million at October 4, 2026 against ~$2.77 billion of total debt, after the EUR 500.0 million 1.875% notes were repaid at maturity in July for ~$571.2 million. Remaining notes mature in 2028, 2029, two 2031 tranches and 2051, plus a $1.5 billion revolver running to January 2030. Goodwill was ~$6.61 billion and net intangibles ~$2.22 billion at July 5, 2026.
  • Market pricing: The shares closed at ~$145.23 on November 20, 2026 against a 52-week range of ~$81.22 to ~$171.74, giving a market capitalization of ~$16.2 billion. Trailing GAAP P/E is ~65x on ~$2.25 of trailing EPS; against ~$5.44 of 2026 consensus adjusted EPS the multiple is ~27x, and against the ~$5.96 analysts expect for 2027 it is ~24x. Price-to-sales is ~5.5x on trailing revenue, and EV/EBITDA is ~21x. The analyst mean target is ~$171.40 across 15 analysts.
  • Dividend and buyback: The quarterly dividend is $0.07 a share, $0.28 annualized, for a yield of roughly 0.18% at the November 20, 2026 price and a payout of about 12% of trailing GAAP earnings. Repurchases do the heavy lifting instead: ~$820.8 million in fiscal 2025 and ~$102.5 million in the first half of 2026, cutting weighted average diluted shares to ~111.7 million from ~118.9 million year over year.

As of November 2026: The multiple depends entirely on which earnings line an owner treats as economic. A trailing GAAP P/E near 65x reflects ~$340 million a year of amortization on intangibles Revvity paid cash for in prior years; a multiple near 27x on 2026 consensus adjusted EPS, or about 24x on 2027 consensus, treats that amortization as sunk. After a roughly 48% gain in 2026 the stock carries a premium closer to faster-compounding life-science tools names than to slow-growth diagnostics, while reported revenue grew only about 4.3% in the third quarter. The fourth-quarter report, expected around February 1, 2027, is the next test of whether margin, buybacks and the instrument backlog can carry that premium.

Which ETFs hold Revvity, Inc. (RVTY)?

If you want RVTY exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in RVTYExpense ratio
RSPInvesco S&P 500 Equal Weight ETF0.25%0.20%

Who competes with Revvity, Inc. (RVTY)?

Life-science tools, reagents and instruments

Revvity's ~$601 million half-year Life Sciences Solutions line competes with Thermo Fisher Scientific, Danaher (through Beckman Coulter Life Sciences, Molecular Devices and Cytiva), Agilent Technologies, Bruker, Bio-Rad Laboratories, Bio-Techne, Qiagen and Merck KGaA's MilliporeSigma unit. Competition runs product line by product line rather than company by company: labeling and detection chemistry against Thermo and Bio-Techne, high-content imaging platforms such as Opera Phenix against Molecular Devices and Yokogawa, and multi-omics sample prep against Qiagen and 10x Genomics. All of these vendors sell to the same pharmaceutical R&D and academic budgets, so they rise and fall on the same funding cycle.

Immunoassay and newborn screening diagnostics

The EUROIMMUN autoimmune and allergy immunoassay business runs against Thermo Fisher's Phadia allergy franchise, Werfen's autoimmunity line, Roche Diagnostics, Abbott, Siemens Healthineers and bioMérieux, all of which hold large installed bases in clinical laboratories. Newborn screening is a narrower field where Revvity is unusually strong, with Bio-Rad, Waters (through mass-spectrometry based screening), Trivitron and Baebies among the alternatives, and with sequencing vendors including Illumina entering from the genomic side as programs such as the Genomics England contract move screening toward whole-genome approaches. Purchasing here is often by public-health authority rather than by individual hospital, which makes contracts large, slow and sticky.

Scientific software and R&D informatics

Signals competes for pharmaceutical R&D informatics budgets with Dotmatics, now owned by Siemens, plus Benchling, Dassault Systemes BIOVIA, Certara, Schrodinger on the modeling side and the LIMS incumbents including LabWare and Thermo's SampleManager. The ACD/Labs acquisition in early 2026 pushed Revvity further into analytical characterization and molecular design, territory Bruker and Waters also occupy through their own informatics products. Software is the smallest of Revvity's four product lines at ~$119.5 million for the half, and its subscription base is the reason a 20% organic decline in one quarter was described as timing rather than churn.

What stocks are similar to Revvity, Inc. (RVTY)?

Other names that sit close to RVTY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Revvity, Inc. (RVTY)

There are three common ways to get RVTY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (RSP), which spreads the position across many companies. Or build it into a focused thematic portfolio, so RVTY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RVTY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Revvity, Inc. (RVTY)

On November 20, 2026 RVTY trades near $145, up about 48% year to date and about 55% over the past year, on ~$2.94 billion of trailing revenue after a third quarter that beat estimates on both revenue and adjusted EPS. Trailing GAAP EPS is ~$2.25 while analysts expect ~$5.44 of adjusted EPS for 2026 and ~$5.96 for 2027, and the difference is almost entirely purchase-accounting amortization, so the choice of earnings figure moves the multiple between roughly 24x on next year's expected earnings and roughly 65x on trailing GAAP.

More on Revvity, Inc. (RVTY)

Whether RVTY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RVTY a buy or a sell?, and where the stock could go from here in the RVTY stock forecast.

For income investors, whether RVTY pays a dividend and how the payout looks is covered in does RVTY pay a dividend? And to weigh RVTY against a peer, read the full side-by-side comparisons: RVTY vs TMO and RVTY vs DHR.

Wondering how RVTY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Revvity, Inc.

Ask Walnut's AI anything about RVTY and see how it fits what you own.

FAQ

What does Revvity do?

+

Revvity sells the reagents, instruments, software and diagnostic tests used in life-science research and in clinical laboratories. Two segments of nearly equal size do the work. Life Sciences (~$720.5 million in the first half of fiscal 2026) supplies detection chemistry, labeling reagents, automation, high-content imaging systems and the Signals informatics suite to pharmaceutical and biotech R&D groups. Diagnostics (~$720.3 million) supplies EUROIMMUN immunoassays for autoimmune, allergy and infectious disease testing, plus newborn and prenatal screening products used by public-health programs. About 11,000 employees serve customers in more than 160 countries, and the company has been a member of the S&P 500 through the transition. Much of the revenue is consumable or subscription based, since assays and screening kits are reordered continuously.

Is Revvity the same company as PerkinElmer?

+

Same SEC registrant, different business. The legal entity is CIK 0000031791, which filed as EG&G, then as PerkinElmer, and now as Revvity, Inc. In March 2023 it sold the Applied, Food and Enterprise Services businesses (the analytical instruments side) to funds managed by New Mountain Capital for approximately $2.136 billion at closing, and the agreement transferred the PerkinElmer brand and trademarks to the buyer as well, with $75 million of deferred payments tied to it. A separate private company now trades on the PerkinElmer name. Anything written about PerkinElmer's chromatography, spectroscopy or food-safety instrument lines describes a business Revvity no longer owns. EDGAR still classifies the registrant under SIC 3826, Laboratory Analytical Instruments, which is a leftover code rather than a description.

Why is RVTY's P/E ratio so high?

+

Trailing GAAP earnings are ~$253 million, or ~$2.25 a diluted share for the twelve months to October 4, 2026, which against a ~$145.23 share price on November 20, 2026 gives a P/E near 65. The number is depressed by amortization of intangible assets, which ran ~$84.9 million in the June quarter alone, or $0.76 a share, and ~$170.0 million for the first half. Those charges are the accounting tail of past acquisitions such as EUROIMMUN and BioLegend, carried as ~$6.61 billion of goodwill and ~$2.22 billion of net intangibles. Add back amortization, restructuring and a few smaller items and adjusted EPS was $1.37 in the September quarter, with analysts expecting ~$5.44 for full-year 2026. On that basis the multiple is roughly 27x on 2026 consensus and about 24x on the ~$5.96 analysts expect for 2027. Both numbers are real; they measure different things.

Why did Revvity stock go up in 2026?

+

The shares closed at ~$145.23 on November 20, 2026, up about 48% year to date and about 55% over one year, after reaching a 52-week high of ~$171.74 (they were ~$124.75 on August 21). The first leg of the move followed a run of results that beat the company's own plan. Second-quarter revenue of ~$729.7 million and adjusted EPS of $1.41 came in above expectations, adjusted operating margin expanded to 28.9% from 26.6%, and management raised full-year guidance on August 4, 2026 to 4% to 5% pro forma organic growth and $5.30 to $5.40 of adjusted EPS. Diagnostics grew 11% organically. Management also pointed to the strongest instrument backlog in three to four years, driven by AI-related drug discovery demand. A one-off $16.2 million tariff refund helped that quarter's margin and is not a recurring item. The rally continued through September and October, several brokers lifted price targets, including TD Cowen to $175 and Evercore ISI to $165, and third-quarter results then beat again ($1.37 of adjusted EPS against $1.30). The shares have since given back about 8.5% over the month to November 20.

Is RVTY a good dividend stock?

+

The dividend is small and clearly not the point of owning the shares. Revvity pays $0.07 a quarter, $0.28 annualized, which at ~$145.23 on November 20, 2026 works out to a yield of roughly 0.18%. Against trailing GAAP EPS of ~$2.25 the payout ratio is about 12%, and against adjusted earnings it is nearer 5%, so coverage is not the constraint. The company returns cash mainly through repurchases instead: ~$820.8 million in fiscal 2025 and ~$102.5 million in the first half of 2026, which took weighted average diluted shares from ~118.9 million to ~111.7 million year over year. Income-focused screens will filter this name out on yield alone. Investors looking for per-share compounding get it through the shrinking share count rather than the cheque.

Who are Revvity's competitors?

+

Competition differs by segment. In life-science tools Revvity runs against Thermo Fisher Scientific, Danaher, Agilent, Bruker, Bio-Rad, Bio-Techne, Qiagen and MilliporeSigma, all selling reagents and instruments into the same pharmaceutical and academic budgets. In immunodiagnostics the EUROIMMUN franchise competes with Thermo Fisher's Phadia allergy business, Werfen, Roche Diagnostics, Abbott, Siemens Healthineers and bioMerieux. Newborn screening is narrower, with Bio-Rad, Waters, Trivitron and Baebies as the main alternatives, and sequencing vendors such as Illumina pressing in from the genomic direction. In R&D software Signals faces Dotmatics (owned by Siemens), Benchling, Dassault Systemes BIOVIA, Certara and the established LIMS vendors. Few competitors overlap with Revvity across all four product lines.

What is Revvity selling in China and why does it matter?

+

On July 31, 2026 Revvity signed a definitive agreement to divest its immunodiagnostics business in China, disclosed in the 10-Q as roughly 6% of fiscal 2025 revenue, with closing expected by the end of 2027 subject to customary conditions and regulatory approval. Chief executive Prahlad Singh described China as a structurally more challenging environment for that unit. The practical consequence for anyone reading the numbers is that guidance is now given only on a pro forma basis excluding the business, so guided full-year revenue of $2.83 to $2.86 billion is below trailing reported revenue of ~$2.94 billion (twelve months to October 4, 2026) without implying a decline. Asia revenue fell to ~$175.1 million in the June quarter from ~$193.1 million. Immunodiagnostics outside China grew high single digits over the same period.

What are the biggest risks to Revvity's business?

+

Four stand out, plus valuation after a roughly 48% gain in 2026. Pharmaceutical and biotech customers cut instrument and software spending first when budgets tighten, and pharma and biotech sales still declined mid-single digits including software in the June quarter. The $16.2 million of tariff refunds recorded in cost of revenue is non-recurring, flattering both gross margin and adjusted EPS in 2026, and Revvity books such refunds only on receipt with no receivable recorded. Goodwill of ~$6.61 billion and net intangibles of ~$2.22 billion sit against ~$7.23 billion of equity, so an impairment at any acquired franchise would be large. And the China divestiture will not close until as late as the end of 2027, leaving a declining business inside reported results for up to five more quarters. Restructuring affecting roughly 5% of the workforce adds execution risk on top.

How did Revvity do in its latest quarter?

+

In the quarter ended October 4, 2026, Revvity reported adjusted EPS of $1.37 against a consensus estimate of $1.30, its fourth straight beat after $1.41 against $1.22 in the June quarter and $1.06 against $1.01 in the March quarter. Revenue was ~$709.6 million, up about 4.3% year over year and above the ~$695 million consensus, and GAAP net income was ~$62.3 million. Fourth-quarter 2026 results are expected around February 1, 2027, with consensus of about $1.62 per share on about $762 million of revenue.

How has RVTY stock performed in 2026?

+

As of November 20, 2026 RVTY closed near $145.23, up about 48% year to date, about 55% over the past year and about 16% over the past three months, but down about 8.5% over the past month, within a 52-week range of ~$81.22 to ~$171.74. The market value is about $16.2 billion. The share price is below the analyst mean target of about $171.40 across 15 analysts, after Barclays raised its target to $175 from $160 on November 4. Walnut is not an investment adviser, and this is not a recommendation.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Revvity, Inc.'s investor relations page or your broker before making investment decisions.